Omeros Corp (OMER)

21.84
0.57 2.68
NASDAQ : Health Care
Prev Close 21.27
Open 21.28
Day Low/High 21.00 / 22.05
52 Wk Low/High 8.90 / 30.23
Volume 579.76K
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 43.94M
Market Cap 915.70M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 3 Small Biotechs Have a Healthy Shot

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.

Give These 3 Small Biotechs a Shot

Give These 3 Small Biotechs a Shot

Several firms hiked price targets on Portola into the $70s this week.

Commit To Purchase Omeros Corp At $16, Earn 17.5% Annualized Using Options

Commit To Purchase Omeros Corp At $16, Earn 17.5% Annualized Using Options

Investors considering a purchase of Omeros Corp shares, but cautious about paying the going market price of $22.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $16 strike, which has a bid at the time of this writing of $1.80.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

FDA Grants Breakthrough Therapy Designation To Omeros' MASP-2 Inhibitor OMS721 For The Treatment Of IgA Nephropathy

Omeros Corporation (NASDAQ: OMER) today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy.

Omeros Announces OMS721 Presentation At 54th ERA-EDTA Congress

Omeros Corporation (NASDAQ: OMER) today announced that data from the company's Phase 2 clinical trial of OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy and other kidney diseases will be presented at the 54th...

3 Small Biotech Value Plays

3 Small Biotech Value Plays

These stocks will be great stories in the second half of 2017, and are significantly undervalued.

Omeros Announces Completion Of IgA Nephropathy Cohort In OMS721 Phase 2 Clinical Trial

Omeros Corporation (NASDAQ: OMER) today announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company's Phase 2 clinical trial of OMS721 for the treatment of...

Omeros Corporation Reports First Quarter 2017 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation To Announce First Quarter 2017 Financial Results On May 10, 2017

Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its first quarter 2017 financial results for the period ended March 31, 2017, on Wednesday, May 10, 2017, after the market closes.

We're in the Middle of the Rally

But this rally has been very much one of fits and starts.

Biotech Movers: Organovo, Endo, Omeros

Biotech Movers: Organovo, Endo, Omeros

Organovo, Endo and Omeros were among the biotech stock moves in premarket trading on Thursday.

Biotech Movers: OncoMed, Incyte, Omeros

Biotech Movers: OncoMed, Incyte, Omeros

OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.

Freeport McMoRan, Wix, Zions Bancorporation: 'Mad Money' Lightning Round

Freeport McMoRan, Wix, Zions Bancorporation: 'Mad Money' Lightning Round

Jim Cramer says hold off before jumping into Freeport McMoRan, Wix.com and Zions Bancorporation.

Fed Crashes the Party: Cramer's 'Mad Money' Recap (Wednesday 4/5/17)

Fed Crashes the Party: Cramer's 'Mad Money' Recap (Wednesday 4/5/17)

Jim Cramer stresses discipline here because, he says, a frothy market can quickly turn on investors.

The Dip Buyers Aren't Delivering Much Right Now

The Dip Buyers Aren't Delivering Much Right Now

The indices are holding key support, but this isn't translating into any real momentum.

Omeros To Present At The Needham Healthcare Conference

Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.

Biotech Premarket Movers: Halozyme, Omeros, Aralez

Biotech Premarket Movers: Halozyme, Omeros, Aralez

Halozyme Therapeutics, Omeros and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Omeros Reports More Positive Data In OMS721 Phase 2 Trial In Renal Diseases

Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the company's Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, which frequently lead to end-stage renal disease...

Noteworthy Tuesday Option Activity: OMER, STOR, RRGB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 4,225 contracts have traded so far, representing approximately 422,500 underlying shares. That amounts to about 75.1% of OMER's average daily trading volume over the past month of 562,750 shares.

Omeros Announces OMS721 Presentation At Annual Meeting of The European Society For Blood And Marrow Transplantation

Omeros Corporation (NASDAQ: OMER) today announced presentation of a case report describing resolution of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a dialysis- and...

Omeros To Present Results From Dose-Ranging Stage Of OMS721 Clinical Trial In Atypical Hemolytic Uremic Syndrome At World Congress Of Nephrology

Omeros Corporation (NASDAQ: OMER) today announced that data from the dose-ranging stage of the Phase 2 clinical trial evaluating OMS721 in the treatment of atypical hemolytic uremic syndrome (aHUS) will be presented next...

Health Care Vote: Bad Medicine for Market?

I don't understand why this is considered a make-or-break moment.

First Week of November 17th Options Trading For Omeros (OMER)

Investors in Omeros Corp saw new options begin trading this week, for the November 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Omeros Corporation Reports Fourth Quarter And Year-End 2016 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

These heavily shorted stocks could get squeezed higher if they report positive earnings this week.

Omeros Corporation To Announce Fourth Quarter And Year-End 2016 Financial Results On March 16, 2017

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2016 financial results for the period ended December 31, 2016, on Thursday, March 16, 2017, after the market...

Commit To Purchase Omeros Corp At $8, Earn 14.1% Annualized Using Options

Investors considering a purchase of Omeros Corp shares, but tentative about paying the going market price of $11.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $8 strike, which has a bid at the time of this writing of 50 cents.